“Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial,” by Bente L. Langdahl, Cesar Libanati, Daria B. Crittenden, Michael A. Bolognese, Jacques P. Brown, Nadia S. Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S. Finkelstein, Harry K. Genant, Stefan Goemaere, Lars Hyldstrup, Esteban Jodar-Gimeno, Tony M. Keaveny, David Kendler, Peter Lakatos, Judy Maddox, Jorge Malouf, Fabio E. Massari, Jose Fernando Molina, Maria Rosa Ulla, and Andreas Grauer (Vol. 390, No. 10102, September 30, 2017, p. 1585-1594).
www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31613-6/abstract
